Want to join the conversation?
$AMGN said its six growth products, Prolia, XGEVA, Enbrel, Sensipar, Vectibix and Nplate, continued to drive the company's overall performance with 13% YoverY growth. The company stated that these six products aggregated to $3Bil of sales or over 50% of 2Q16 sales.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?